tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

ResMed price target raised to $325 from $285 at UBS

UBS analyst Marcus Curley raised the firm’s price target on ResMed (RMD) to $325 from $285 and keeps a Buy rating on the shares. ResMed posted “solid” Q4 results, as well as “comfort” on patient starts, PAP share, resupply, and gross margin expansion, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1